Newsroom

Mallinckrodt plc Celebrates 20 Years of Successful Operations in Ireland

Newly independent global specialty pharmaceuticals company marks spin-off and anniversary

DUBLIN--(BUSINESS WIRE)--Nov. 6, 2013-- Today, Mallinckrodt plc (NYSE: MNK) celebrates its official launch as a public limited company (plc) in Ireland, as well as the 20th anniversary of the opening of its Dublin manufacturing plant at its facilities in Damastown Industrial Park. The event – whose honored guests include Leo Varadkar, M.D., T.D., Minister for Transport, Tourism and Sport for the Government of Ireland, and Mark Trudeau, President and CEO of Mallinckrodt – celebrates the global specialty pharmaceuticals company strong Irish heritage and its commitment to driving future growth and manufacturing excellence.

Over the span of two decades of operations in Ireland, Mallinckrodt has employed hundreds of local citizens and made investments in the community at large. The company’s manufacturing facility produces a major bulk active pharmaceutical ingredient for contrast media, manufactures clinical-trial material and performs drug product release for imaging and pharmaceutical products for markets in Europe.

Mallinckrodt has also been an active supporter of JobBridge, the government-sponsored internship placement program, for the past 18 months. Through JobBridge, these interns have developed and enhanced their skills at Mallinckrodt’s state-of-the-art facilities.

“We are incredibly proud of our long-standing presence in Ireland, the investment we have made in the local community and our talented staff who embody quality, integrity and service every day,” said Mr. Trudeau. “Our Dublin plant is one of the top-performing sites within Mallinckrodt, and a key growth driver as we continue to unlock our potential as a leading global specialty pharmaceuticals company.”

To date, Mallinckrodt has made a capital investment of more than €100 million, and plans to grow in the years ahead. Building on its commitment to deliver the highest level of quality products and services reliably and safely, the company is developing the Dublin plant as a knowledge centre of excellence within Mallinckrodt for continuous improvement processes.

“The healthcare industry offers continued potential to create jobs and grow our economy, as well as contribute to the health and well-being of our citizens,” said Minister Varadkar. “Mallinckrodt’s investment in and partnership with the Irish community is a valued example of this. We look forward to 20 more years together, and beyond.”

In Dublin, Mallinckrodt employs more than 100 individuals in its Principle Executive Office and Manufacturing Facility. The 82,000-square-foot state-of-the-art, facility has produced ioversol, a bulk active pharmaceutical ingredient for contrast media, since 1993.

Mallinckrodt became a plc in January 2013, to hold the pharmaceuticals business of Covidien, which was spun off on June 28, 2013.

ABOUT MALLINCKRODT:

Mallinckrodt is a global specialty pharmaceuticals business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 70 countries. The company’s 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Source: Mallinckrodt plc

Mallinckrodt plc
Lynn Phillips, 314-654-3263
Manager, Media Relations
lynn.phillips@mallinckrodt.com
or
Meredith Fischer, 314-654-3318
Senior Vice President, Communications
meredith.fischer@mallinckrodt.com
or
John Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com